UBIX THERAPEUTICS

ubix-therapeutics-logo

Ubix Therapeutics is a research and development company that develops anti-cancer drugs.

#SimilarOrganizations #Financial #Website #More

UBIX THERAPEUTICS

Social Links:

Industry:
Biotechnology Medical

Founded:
2018-01-01

Address:
Seoul, Seoul-t'ukpyolsi, South Korea

Country:
South Korea

Website Url:
http://www.ubixtrx.com

Total Employee:
1+

Status:
Active

Contact:
+82 2 6335 2475

Email Addresses:
[email protected]

Total Funding:
19 B KRW

Technology used in webpage:
Euro CrUX Top 50m CrUX Dataset Pound Sterling Japanese Yen


Similar Organizations

polymed-biopharmaceuticals-logo

Polymed Biopharmaceuticals

Polymed Biopharmaceuticals is a drug research and development company.

proabtech-logo

ProAbTech

ProAbTech is a research and development company that develops conjugated biological drugs.

pyxis-diagnostics-logo

Pyxis Diagnostics

Pyxis Diagnostics is a biotechnology company that develops cancer diagnostics platforms.

ribomic-logo

RIBOMIC

R&D medicine based on their own platform for developing medicine

Investors List

dayli-partners_image

Dayli Partners

Dayli Partners investment in Series B - Ubix Therapeutics

utc-investment-co_image

UTC Investment Co.

UTC Investment Co. investment in Series B - Ubix Therapeutics

premier-partners_image

Premier Partners

Premier Partners investment in Series B - Ubix Therapeutics

korean-development-bank_image

Korea Development Bank

Korea Development Bank investment in Series B - Ubix Therapeutics

atinum-partners_image

Atinum Partners

Atinum Partners investment in Series B - Ubix Therapeutics

partners-investment_image

Partners Investment

Partners Investment investment in Series B - Ubix Therapeutics

mirae-asset-venture-investment_image

Mirae Asset Venture Investment

Mirae Asset Venture Investment investment in Series A - Ubix Therapeutics

premier-partners_image

Premier Partners

Premier Partners investment in Series A - Ubix Therapeutics

Official Site Inspections

http://www.ubixtrx.com Semrush global rank: 5.52 M Semrush visits lastest month: 1.32 K

  • Host name: 211.37.149.157
  • IP address: 211.37.149.157
  • Location: South Korea
  • Latitude: 37.5112
  • Longitude: 126.9741
  • Timezone: Asia/Seoul

Loading ...

More informations about "Ubix Therapeutics"

Ubix Therapeutics - Crunchbase Company Profile & Funding

Organization. Ubix Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email [email protected]; Phone โ€ฆSee details»

(์ฃผ)Ubix Therapeutics

We are driven to utilize research and technology to innovate therapeutics and to help livesSee details»

(์ฃผ)Ubix Therapeutics - ubixtrx.com

HS Hong is the director of Chemistry, Manufacturing, and Controls at Ubix Therapeutics. Ms. Hong holds over 21 years of broadly diversified experience in pharmaceutical industry, having โ€ฆSee details»

Ubix Therapeutics - LinkedIn

Saving lives by driving innovations in targeted protein degradation (TPD) therapeutics. Ubix Therapeutics is a preclinical-stage biotechnology company with full capacity for TPD โ€ฆSee details»

Ubix Therapeutics Co. Ltd. - Drug pipelines, Patents ... - Patsnap

Explore Ubix Therapeutics Co. Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 6 news, and 2 literature, Disease Domain:Neoplasms, Immune System Diseases, โ€ฆSee details»

Ubix Therapeutics - Overview, News & Similar companies

Mar 23, 2020 Debiopharm And Ubix Therapeutics Launch Research To Develop A New Anti-Cancer Modality - Antibody Degraducer® Conjugates LAUSANNE, Switzerland and SEOUL, โ€ฆSee details»

(์ฃผ)Ubix Therapeutics - en.ubixtrx.com

05836) #1401, 7, Beobwon-ro 11-gil, Songpa-gu, Seoul, Republic of Korea Tel +82.2.6335.2475 Fax +82.2.6334.2475 [email protected]See details»

(์ฃผ)Ubix Therapeutics - ubixtrx.com

Ubix Therapeutics develops novel anti-cancer drugs based on Degraducer® platform technology. Degraducer® is a powerful, next-generation inhibitor technology that enables targeting of โ€ฆSee details»

(์ฃผ)Ubix Therapeutics

(05836) ์„œ์šธํŠน๋ณ„์‹œ ์†กํŒŒ๊ตฌ ๋ฒ•์›๋กœ11๊ธธ 7, ๋ฌธ์ •ํ˜„๋Œ€์ง€์‹์‚ฐ์—…์„ผํ„ฐ C๋™ 1401ํ˜ธ Tel 02-6335-2475 Fax 02-6334-2475 [email protected] โ“’ Ubix TherapeuticsSee details»

UBIX THERAPEUTICS, SK BIOPHARMACEUTICALS ENTER INTO โ€ฆ

Apr 14, 2022 For more information, visit Ubix Therapeuticsโ€™ website at www.ubixtrx.com. About SK Biopharmaceuticals. SK Biopharmaceuticals and its U.S. subsidiary SK life science are โ€ฆSee details»

UBX-103 - Drug Targets, Indications, Patents - Synapse - Patsnap

SEOUL, South Korea I January 02, 2024 I Ubix Therapeutics, Inc., a biotechnology company developing innovative oncology therapeutics based on targeted protein degradation (TPD), โ€ฆSee details»

Ubix Therapeutics Receives US FDA Clearance to Proceed with

Seoul, South Korea, Jan. 02, 2024 -- Ubix Therapeutics, Inc., a biotechnology company developing innovative oncology therapeutics based on targeted protein degradation (TPD), โ€ฆSee details»

Debiopharm and Ubix Therapeutics Launch Research to Develop a โ€ฆ

Jun 16, 2021 LAUSANNE, Switzerland and SEOUL, South Korea, June 16, 2021 /PRNewswire/ -- Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company โ€ฆSee details»

UBIX THERAPEUTICS KICK OFF AN IND-ENABLING STUDIS OF โ€ฆ

Jul 19, 2021 Seoul, Republic of Korea โ€“ July 20 th, 2021 โ€“ South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead โ€ฆSee details»

(์ฃผ)Ubix Therapeutics - ubixtrx.com

Seoul, Republic of Korea โ€“ July 20th, 2021 โ€“ South Korea-based biotech company, Ubix Therapeutics (www.ubixtrx.com), announced the current status of their lead program, UBX โ€ฆSee details»

UBIX THERAPEUTICS KICK OFF AN IND-ENABLING STUDIS OF

Jul 20, 2021 Seoul, Republic of Korea โ€“ July 20th, 2021 โ€“ South Korea-based biotech company, Ubix Therapeutics (en.ubixtrx.com), announced the current status of their lead program, UBX โ€ฆSee details»

Ubix โ€“ a cancer research based on Multilinkโ„ข Degraducer®

Jun 16, 2021 Lausanne, Switzerland, Seoul, Republic of Korea โ€“ June 16th, 2021 โ€“ Debiopharm (www.debiopharm.com), a Swiss-based global biopharmaceutical company and Ubix โ€ฆSee details»

(์ฃผ)Ubix Therapeutics - en.ubixtrx.com

In the case that structural information of target proteins is known, we have the potential to utilize in silico screening for 1) discovery of new binders, 2) acquisition of background information for โ€ฆSee details»

(์ฃผ)Ubix Therapeutics - ubixtrx.com

For more information, visit Ubix Therapeuticsโ€™ website at www.ubixtrx.com. About SK Biopharmaceuticals SK Biopharmaceuticals and its U.S. subsidiary SK life science are global โ€ฆSee details»

(์ฃผ)Ubix Therapeutics - ubixtrx.com

We are conducting novel E3 ligase research on new mechanisms as well as binders of previously known E3 ligase such as CRBN, VHL, and IAP, and are carrying out pharmaceutical research โ€ฆSee details»

linkstock.net © 2022. All rights reserved